Jul 2, 2024, 08:55
Mark Wildgust: Another incredible milestone for our JNJOncology team!
Mark Wildgust,
The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on LinkedIn:“Another incredible milestone for our JNJOncology team!.
As this team continues to make strides to advance the science of Lung Cancer, I look forward to what’s to come in the treatment of this disease.”
Read further.
Source: Mark Wildgust/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 00:34
Oct 22, 2024, 00:24
Oct 21, 2024, 19:26
Oct 21, 2024, 19:21
Oct 21, 2024, 19:17
Oct 21, 2024, 19:14
Oct 21, 2024, 19:10